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ABSTRACT
Objectives: Rheumatoid arthritis (RA) patients show low serum levels of the Ag dipeptidyl 
peptidase IV (DPP-IV/CD26), both soluble CD26 (sCD26) concentration and its DPP-IV 
activity. The aim of this study was to test if anti-DPP-IV/CD26 Abs (Anti-CD26) cleared 
sCD26. 
Design & Methods: Serum Anti-CD26 and Total titers (as comparison) of isotypes IgA, IgM 
and IgG as well as sCD26 concentration and DPP-IV activity were measured in a cohort of 
RA patients undergoing different biological and non-biological therapies (n=105) and 
controls (n= 50). 
Results: Anti-CD26 levels were increased approximately two-fold for each isotype in RA, 
were not related to the sCD26 clearance, showed several correlations with disease activity 
parameters, were significantly higher in smokers and they were not ACPA. Anti-CD26 Igs 
showed high diagnostic power (82% sensitivity and 96% specificity) and their levels differed 
amongst the different groups of patients stratified by the type of therapy.
Conclusions: As DPP-IV/CD26 is an associated to factors triggering RA in the lung and 
periodontal tissue, these results suggest that Anti-CD26 isotypes may participate in 
pathogenesis and may be useful as biomarkers for earlier diagnosis and/or precision medicine.
































































Investigations on anti-citrullinated protein antibodies (ACPA) have revealed 
information about the antigen specificity that initiates or perpetuates inflammatory 
autoimmune reactions before rheumatoid arthritis (RA) disease onset. For example, aberrant 
post-translational modifications of self-proteins such as citrullinated vimentin, type II 
collagen, fibrinogen and alpha enolase do play a role in breaking T and B cell tolerance [1,2] 
outside the joints. Lungs, lymph nodes and gingival tissues were identified as places where 
RA pathogenesis starts [3-7]. Among the environmental factors triggering autoimmunity in 
RA, tobacco induces citrullination of proteins in the lung and ACPA production in genetically 
predisposed subjects [1-12]. An additional trigger of autoimmunity is the link between 
periodontal or gingival disease and RA. In this case, the external agent is the oral microbiome 
with Porphyromonas gingivalis as the main (but not unique) suspect [29]. P gingivalis is one 
of few bacteria that express deiminase, the enzyme that produces citrulline, so may play a 
pathogenic role in ACPA-positive RA patients [30]. 
However, clinical data of serological biomarkers such as concentration of ESR, CRP, 
the presence of ACPA and/or rheumatoid factor or other auto-Abs [11-13], are not enough for 
this very early detection. For example, sensitivity of ACPA is about 75% in established RA 
compared with 55% in early RA and 40% in very early RA [1,14]. This is neither useful for 
disease progression monitoring or responsiveness to therapy. It can be also deduced that if we 
attempt to obtain tools for earlier diagnosis or earlier pathogenesis events that might be 
targeted with preventive or therapeutic measures, it may be beneficial to look for self-antigens 
with higher titers of auto-Abs in serum than in synovial fluid, in which the event occur later 
[2,3,5,7-10].






























































[15,16]. DPP-IV as a result of its N-terminal X-Pro cleaving activity, regulates chemotactic 
responses to inflammatory chemokines, including SDF-1, and biologically active peptides 
such as NPY and VIP, recently implicated in RA. DPP-IV is also a neutrophil chemorepellent 
[17,18]. Interestingly, the biofilm formation and production of DPP-IV are correlated in P 
gingivalis, and both are important factors of virulence in periodontitis in a mouse model [31]. 
Also, stimulants such as cytokines or bacterial components from P gingivalis, Prevotella 
intermedia, and Escherichia coli augment the CD26 expression by gingival fibroblasts [32].
Several authors, including ourselves [18,22-24], have shown lower levels of sCD26 
(as well as DPP-IV activity) in RA patients and found important correlations between CD26 
expression on some T cell subsets with disease activity (DAS28) and sCD26 serum levels 
[18]. Autoantibodies against DPP-IV (Anti-CD26) were predicted as a possible way to clear 
soluble DPP-IV (sCD26) from the circulation [19] via bile secretion in the form of IgA-Ag 
complexes [20]. Although high titers of Anti-CD26 IgA were shown in patients of some 
autoimmune diseases with lower circulating sCD26 serum levels [21], supporting this role, 
the same result was not detected in RA patients [21]. We evaluated the levels of Anti-CD26 

































































One hundred and ten patients from the Rheumatology Service (Hospital Meixoeiro-
CHUVI) were recruited in a cross-sectional case-control study. Patients fulfilled the American 
College of Rheumatology (ACR)/EULAR criteria of 2010 [3] and were on different therapies, 
including biological therapies (BT). The 110 RA patients consisted of 82 women and 28 men. 
Mean age was 57 years (range: 24– 78). The only exclusion criterion was the patient´s 
decision not to be included in the study. Mean disease duration was 12 years (range: 0.5– 41). 
A group of 50 healthy donors was also recruited (women, n = 21, men, n = 29). Mean age was 
44 years (range: 18–62). All the procedures described were performed according to clinical 
ethical practices of the Spanish and European Administrations and approved by the local 
ethics committee (CEIC Galicia (Xunta de Galicia), code nº 2010/298 and Agencia Española 
de Medicamentos y Productos Sanitarios (Ministerio de Sanidad) nº PYC-INM-2011-01). 
Written informed consent was obtained from all participants. 
2.2. Assessment of Disease Activity
Disease activity was assessed by the DAS-28 index, which takes into account the 
number of tender joints, swollen joints, erythrocyte sedimentation rate (ESR) and Patient 
Global Assessment (PGA) of disease activity, scored by a numeric rating scale (NRS 0–100). 
Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), haemoglobin and platelet 
concentration levels were also recorded as RA activity markers. All patients also completed 
































































Patients’ smoking history was evaluated at inclusion. Current smokers were those 
reporting active smoking. Past smokers were all patients who had stopped smoking before the 
first examination at inclusion. Non-smokers reported no history of smoking at any time.
These data, together with other such as the measures of disease activity and others, 
were included in a specifically designed database. Some of the most relevant data has been 
published before [18].
2.4. Measurement of DPP-IV Enzyme Activity and Soluble CD26 Protein
Serum collection and both techniques have been described previously [18,21,24]. 
Since previous studies [25-27] have shown not statistically significant differences in both 
levels of sCD26 and DPP-IV activity according to gender or age, values from controls and 
RA patients were not matched for these two parameters.
2.5. Enzyme-linked immunosorbent assays for Total and Anti-CD26 Igs
Concentrations of Total and Anti-CD26 IgA, IgG and IgM in sera of patients were 
determined using 96-well cultured plates coated with rDPP-IV (rsCD26) (0.5 g/mL) (RnD 
Systems, USA) or with polyclonal rabbit anti-human IgA, anti-IgG and anti-IgM (2 g/mL) 
(DakoCytomation, Denmark) prepared in PBS pH 7.4. Coated wells were blocked overnight 
with PBS 0.5% BSA. Plates were incubated with different dilutions of serum for 1 h at 37 ºC. 
Very high dilutions were needed to measure Total Ig types; for Anti-CD26 Igs, between 2 and 
5 L of serum were used. Plates were then washed four times with PBS 0.05% Tween20 
before goat anti-human IgM (-chain), anti IgG (Fab-specific) and IgA (-specific)-
peroxidase conjugates (all from Sigma-Aldrich) were used to detect captured Abs. Standard 






























































four washing cycles. Absorbance at 450 nm was registered using a BioRad Plate reader 
(BioRad, Madrid, Spain). Concentrations were calculated from calibration curves (data not 
shown) constructed with affinity-purified human IgA, IgG or IgM.
2.6. ACPA Test
 Elia™ CCP Test (Thermo Scientific/Phadia, Sweden) was used to analyse whether 
Anti-CD26 Abs were included in ACPA. Briefly, the test was used to bind the ACPA (anti-
CCP antibodies) from patients’ sera to the plate containing CPP Ags, according to the 
manufacturers’ instructions. The remaining serum was recovered as negative-ACPA fraction. 
After washing the Elia-CCP plate to avoid unspecific binding, ACPA were eluted from the 
plate with Elution buffer (0.1 M Glycine-HCl pH 2.7) and this buffer neutralized with 1 M 
Tris-HCl pH 9 to obtain the positive-ACPA fraction. Both fractions were then checked using 
the in-house Anti-CD26 ELISA described in the main text. In the same way, this latter ELISA 
was used to obtain a negative Anti-CD26 Ab fraction (recovery of patients’ serum after Ab 
binding to the plate-bound sCD26 Ag) and a positive-AntiCD26 Ab fraction (obtained after 
washing and elution of the bound Ab), and both fractions analysed using the Elia™ CCP test.
Sera from three RA patients showing high levels of Anti-CD26 IgG isotype and three 
healthy donors were chosen. In all these ELISAs, only reagents to detect the IgG isotype were 
used (see above).
2.7. Statistical Analysis
Kolmogorov-Smirnov was applied to continuous variables to verify normal 
distribution. All analyses were parametric as most groups showed normal distribution 
although some were small. The ANOVA test was carried out to compare variables among the 






























































was used for variables with homogeneous variances and the post-hoc Dunnett´s C test was 
used for variables without homogeneous variances. Dunnett´s T test was performed to 
compare each group with a control group, either the group without BT or the healthy donor 
group. Student´s T-test was also used to compare variables between two groups. 
Anti-CD26 ability to discriminate between RA patients and healthy controls was 
evaluated by receiver operating characteristic (ROC) curves. Sensitivity, specificity, 
likelihood ratios (LRs) and their confidence intervals (CI), positive predictive value (PPV), 
negative predictive value (NPV) and diagnostic accuracy were calculated. To estimate 
positive LR the formula sensitivity/(1-specificity) was applied and the negative LR was 
calculated as (1- sensitivity)/specificity. The cut-off point was chosen as the value that 
rendered the highest accuracy value. 
































































3.1. Anti-CD26/DPP-IV autoantibody and Total Ig levels and their correlations with serum 
DPP-IV activity and sCD26 concentrations in the healthy donor cohort
Mean titers (n=50) of serum Total Ig concentrations for the three isotypes under study 
were found within expected values [28] by the in-house ELISA, 2.37 ±1.24 mg/mL for IgM, 
2.28 ±0.27 mg/mL for IgA and 12.28 ±2.79 mg/mL for IgG. Mean serum Anti-CD26 
autoantibody titers are 13.51 ±5.62 g/mL for IgM, 1.28 ±0.27 g/mL for IgA and 2.14 ±0.64 
g/mL for IgG, being quite similar to those previously published, slightly lower for the IgM 
and IgA isotypes [21]. Comparing their published ratios of anti-CD26 /Total Ig isotype [21] 
with ours (7.12 for IgM, 0.57 for IgA and 0.19 for IgG), our results are more consistent with 
expected values of Total Ig titers [28].
 As demography of control donors and RA patients were slightly (although not 
statistically) different from healthy donors, levels of Igs were compared according to gender 
and age (50 or less years old, 51-60, and 61 or more years old). ANOVA did not show any 
significant difference and the trend to higher IgA levels in elders (data not shown) was only 
significant by the T-test when comparing the younger and the elder groups.
None of the present values, or their ratios, correlated with serum DPP-IV activity or 
sCD26 concentrations in this cohort of healthy donors (data not shown). DPP-IV and sCD26 
levels behaved different according to gender, as previously described [26,27, manuscript in 
preparation]. Interesting, the scarcer IgA isotype levels was close to a significant negative 
correlation (R= -0.529, p= 0.063) with sCD26 in men, where DPP-IV activity and sCD26 
concentration did not correlate. Anti-CD26 IgM and IgG strongly correlated between them 






























































3.2. Serum Anti-CD26 and Total Ig levels in RA patients undergoing different therapies
Analyzing the whole cohort of RA patients (n=106), levels of both Total and Anti-
CD26 Igs were statistically higher compared to healthy donors (T-test p<0.001, most of 
them). Mean ±SD of Total Ig concentrations for each of the three isotypes were 4.33 ±3.79 
mg/mL for IgM, 5.61 ±1.77 mg/mL for IgA and 21.81 ±15.35 mg/mL for IgG. Mean ±SD 
Anti-CD26 concentrations were 27.97 ±19.09 g/mL for IgM, 2.01 ±1.34 g/mL for IgA and 
5.87 ±3.13 g/mL for IgG. Anti-CD26/Total isotype ratios were 17.10 for IgM, 0.43 for IgA 
and 0.75 for IgG. Although all values of Total Igs increased two-fold overall, it is worth 
noting that IgA ratio is lower compared to healthy donors whereas the opposite was found for 
IgM and particularly IgG ratios, higher (next to 4-fold) and significantly different compared 
to healthy donors (p<0.001; ANOVA test), a result that point to the accuracy of our in-home 
ELISA. 
Our patients differed according to therapies and data were calculated for each group, 
noBT (no biological therapy, under DMARDs), anti-TNF, anti-CD20 and anti-IL6R/Ig-
CTLA4 BTs (the latter grouped together because of the similar results) (Table 1). In addition, 
the results for Anti-CD26 were different to that of Total Igs (Supplemental data), which 
underlies the specificity of the ELISA
3.3. Diagnostic power of serum Anti-CD26 levels
We tested whether any of the isotype titers could have diagnostic power, knowing that 
this cohort cannot be properly used for this purpose, as these patients were already 
undergoing therapy. Regardless, for the IgG isotype, which does not change amongst the 
groups, sensitivity of 82% and specificity of 96% was found (Supplemental Figure 2 shows 
ROC curves for the whole cohort) with cut-off 2.85 g/mL. Testing the group undergoing 






























































groups), a sensitivity of 77% (17/22) was found for IgG with the same cut-off (Figure 1 A). A 
similar result, 73% (16/22) sensitivity was found for IgM (in this case with cut-off 20 g/mL) 
(Fig. 1 B) and for IgA (with cut-off 1.8 g/mL) (Fig. 1 C) titers. To note, only 3 out of 22 
patients were negative for both IgG and IgM isotypes and 2/22 for the three.
3.4. Correlations of serum Anti-CD26 levels with disease activity parameters in RA patients
Data of the DAS28 score; the DAS28 components (clinical: TJC, SJC, PGA, and 
laboratory variables: ESR and CRP); or other RA activity markers (HAQ, haemoglobin, 
platelet and haematocrit) were recorded for each patient. Some information was previously 
shown [18]. 
Anti-CD26 levels (like Total Igs) did not correlate with the DAS28 score. However, 
the three Ig isotype titers showed negative correlation with TJC (r= -0.272, p=0.036 for IgM; 
r= -0.210, p=0.032 for IgG; r= -0.273, p=0.005 for IgA). IgG levels also negatively correlated 
with the haematocrit and IgA with ESR (r= -0.360, p<0.001 for the latter). Finally, the ratios 
of IgG and IgA isotypes correlated with the CRP (data not shown).
The same analysis was performed in each group of patients separately, as BT are 
confounding factors. In the noBT group, only the IgA ratio showed a very strong correlation 
with TJC (r= 0.704, p<0.001). In the anti-TNF BT group, Anti-CD26 IgA strongly correlated 
with TJC and DAS28 (Supplemental Fig 3 A and B, respectively) and IgM levels positively 
correlated with TJC (r= 0.295, p=0.024). No correlations were found for the IgG isotype. 
However, in the anti-CD20 BT group, Anti-CD26 IgG correlated strongly with TJC, SJC, 
DAS28 and PGA (Figure 2 A to D) and no correlations were found for the other two isotypes. 
Finally, in the anti-IL6R/Ig-CTLA4 BT group, only the IgG ratio correlated with TJC and 






























































Taken together, the data show: a) a specific relationship between Anti-CD26, the 
joints counts and the DAS, b) Anti-CD26 levels are variably affected by each therapy (or, 
alternatively, they might mark patients responders to each therapy), and c) they provide 
different information to that of most frequently used disease activity parameters (ESR, CRP, 
platelet count, Hb levels or haematocrit).
3.5. Higher serum Anti–CD26 titers in smokers
The whole cohort was divided in three groups according to their smoking status, 
current (n=18), past (n=28) or non-smokers (n=59) and means of the three Anti-CD26 isoypes 
were compared. Whereas IgA titers were similar among the three groups, both IgM and IgG 
showed higher levels in past smokers in particular (26.0 g/mL in non-smokers compared to 
31.8 g/mL in past smokers for IgM, and 5.5 g/mL to 6.7 g/mL for IgG), although these 
differences did not reach statistical significance. 
When the analysis was done in each group of patients (Table 2), in the noBT group 
IgM titers were significantly higher in past smokers compared to non-smokers. Although 
there were few current smoker in this group, they also showed higher titers. The IgG isotype 
also showed a trend to higher titers in past smokers, compared to the other groups, although 
this trend did not reach statistical significance. To note, whereas Anti-CD26 IgG or IgA levels 
did not change among the different therapies, IgM levels were attenuated in past smokers in 
the anti-TNF BT group and in all patients in the anti-CD20 BT group. However, in the anti-
IL6R/Ig-CTLA4 BT group non-smokers showed increased levels of IgM (Table 2).
3.6. Serum Anti-CD26 are not ACPA
Combination of the well-established second-generation Elia™ CCP tool in the clinical 






























































tested, see methods) showed that Anti-CD26 are not ACPA. When supernatants of serum 
from both healthy donors and RA patients were recovered from the ACPA test and tested for 
the presence of Anti-CD26 (Fig. 3 A, RA patients showing highest absorbance levels), a 
similar absorbance to that obtained with the same serum sample used only in the Anti-CD26 
ELISA test (not shown) could be detected. The ACPA test showed the expected results, with 
higher levels in the three patients analyzed than in the three healthy donor samples (except 
one which was also positive) (Fig. 3 B, dark gray).
To verify these results, we also performed the inverse analysis, where supernatants 
recovered from the Anti-CD26 ELISA were then used in the ACPA test. Although 
absorbances were quite similar to those obtained after the direct incubation of the same serum 
in the ACPA test, one healthy donor and one RA patient showed more important differences 
between samples (Fig. 3 B). In these cases, when proteins captured in the Anti-CD26 assay 
were eluted from the plate well and tested in the ACPA assay a minor positive signal was 
observed, pointing to the possibility that a minor part of ACPA autoantibodies may also bind 
to CD26 (data not shown).
3.7. Serum Anti-CD26 isotypes and their correlations with DPP-IV activity and sCD26 
concentrations in RA patients
As in the healthy control group, correlations of the isotypes and their ratios with the 
serum DPP-IV activity and sCD26 concentrations were analysed in our cohort of patients. 
Only next to statistically significant positive correlations were found between Total IgG and 
Anti-CD26 IgG with the sCD26 concentration but not with the enzymatic activity (data not 
shown). 
The same analysis was then performed in each group of patients undergoing different 






























































activity but not with the sCD26 concentration (Figure 4 A); b) In the anti-IL6R/Ig-CTLA4 BT 
group, Total IgM and IgG titers negatively correlated with the DPP-IV activity (Figure 4 D); 
c) In the anti-TNFa group (with increased DPP-IV activity levels), in addition to Total IgA 
and IgM titers, also Anti-CD26 IgG positively correlated with DPP-IV activity (Figure 4 B). 
Only in this group Total IgM and IgG and Anti-CD26 IgG and IgM titers correlate positively 
with the sCD26 concentration (Figure 4 B); d) in the anti-CD20 BT group, with decreased 
levels of IgMs and Igs in general, both Anti-CD26 IgM titers and ratio show a strong negative 
correlation with the sCD26 concentration (Figure 4 C).
It can be concluded that: a) Anti-CD26 isotypes are not related to the impairment of 
sCD26 Ag concentrations in RA patients, since the only correlation (in the anti-TNF BT 
group) was positive; b) different levels of correlation between DPP-IV activity and sCD26 
concentration are found in each group of patients (they do not correlate in the noBT and in the 
anti-IL6R/Ig-CTLA4 BT group and correlate strongest in the anti-CD20 BT group, data not 
shown); c) together with the fact that DPP-IV activity and sCD26 concentration, impaired in 
RA patients and targeted by therapies [18], are related to the same pathway that affected Anti-
CD26 titers, we conclude that DPP-IV activity and sCD26 concentration do not play parallel 
roles in RA pathogenesis; d) different therapies have a profound impact also in these 































































González-Gronow and colleagues observed that myocardial infarction patients who 
received streptokinase (SK) as fibrinolytic therapy developed anti-CD26 autoantibodies as 
well as anti-SK and anti-plasminogen (Pg) auto-Abs [40]. Both Pg and SK bind to CD26 
perhaps explaining the biochemical mechanism that originates these auto-Abs [40]. The 
present work shows important differences to theirs [21,40]. First, in RA and other 
autoimmune diseases they found higher levels of anti-CD26/DPP-IV autoantibodies (Anti-
CD26) of the IgA isotype but not IgG and IgM isotypes. We found additional elevated levels 
of IgM and IgG isotypes, which showed in fact better diagnostic values than IgA. The 
differences between both studies may be related to the fact that we used a recombinant sCD26 
protein as the ELISA Ag instead of sCD26 isolated from patient sera [21], a more complex 
Ag [21,27]. In our data, in contrast to theirs [21], Total Ig isotypes levels fit with their known 
values in human serum [28]. Importantly, in additional experiments we have found people 
with intestinal anomalies where Anti-CD26 levels significantly decreased (manuscript in 
preparation), whereas we also found higher levels of only IgM, or only IgA, respectively, in 
autoimmune diseases such as systemic lupus erythematosus (lower than in RA) and Sjögren 
Syndrome (higher than in RA) (data not shown). 
The expected correlation between lower circulating levels of DPP-IV and the higher 
levels of Anti-CD26 IgA [21,40] was found in healthy men but in RA, only in patients 
undergoing anti-CD20 BT (Fig 4), probably because the reduction of confounding Anti-CD26 
isotype. On the contrary, the correlations found were positive and mostly for the Anti-CD26 
IgG and IgM isotypes in the case of TNFi BT, a therapy that is enhancing the CD26 levels in 
coherence with previous data [41]. It is easy to conclude that Anti-CD26 generally has a much 






























































Although the elevated levels of Anti-CD26 found in most RA patients (present also at 
lower levels in healthy people) may fit in the context of periodontal infection [29-32], the fact 
that in our cohort, past smokers (but no current smokers, perhaps indicating that the former 
smoked a higher amount of cigarettes in their lives) showed elevated levels of Anti-CD26, 
whereas Anti-P gingivalis Ab titers were found to be associated with, on the contrary, non-
smoking status in early RA [29], may rise an alternative scenario of immunological tolerance 
breaking in the lung: CD26/DPPIV expression is enhanced in bronchial epithelial cells 
(BECs) by IL-13 stimulation and may play a role in asthma [34,35]. Type II collagen and 
fibrinogen are typically citrullinated antigens in ACPA-positive RA [5,6], and CD26/DPPIV 
was found bound to proteins of the extracellular matrix as well as fibrinogen (in pleural 
effusions samples) [36]. Intriguingly, DPP-IV and fibrinogen-like 2 (FGL2) genes are 
genomic markers (allele and SNPs frequencies) identified for severe periodontitis [37]. 
That these autoantibodies are not ACPA may be relevant. A recent study in patients 
with periodontitis showed higher titers of Abs against non-citrullinated antigens, suggesting 
that the breaking of tolerance to non-citrullinated peptides could precede later events [33]. B 
cell clones producing mAbs recognizing citrullinated peptides failed to recognize the native 
non-modified arginine version of the peptide [38]. This observation suggests that several 
different target antigens may initially drive the autoimmune responses before being refined 
and focused on one particular epitope. In this sense, it is also remarkable the fact that a 10-
aminoacid long peptide epitope (145-154) of the human CD26/DPP-IV has been recently 
found as an MHC class I-associated peptide (MIPs) by elution from B lymphoblasts (from the 
HLA-B*44:03 allele, www.iedb.org) [39]. Therefore, Anti-CD26 may come from one of 
those early events and provide different diagnostic information than ACPA, however the 






























































Anti-collagen and anti-fibrinogen Ab titers are higher in the synovial fluid [5,6] and 
may be related with the articular damage because mAbs isolated from ACPA-positive B 
lymphocytes stained inflamed synovial tissues from RA patients [38]. Anti-CD26 showed 
intense correlations with the articular damage, even with the DAS28 score, a clear advantage 
with respect to other autoAbs in clinical use (such as ACPA) that do not correlate with 
disease activity [28]. The fact that the isotype IgA, IgM or IgG classes that correlate with TJC 
or DAS28 were different in each group of patients, with each of them showing different 
correlations with parameters of disease activity, supports that they may provide specific 
biological information. In conclusion, autoantibodies against CD26/DPP-IV may participate 
in the pathogenesis of this autoimmune disease, their preliminary clinical value suggesting 
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Figure 1. Cut off values for Anti-CD26 Igs and frequency of anomalous values in RA 
patients of the noBT group (patients under DMARDs) and healthy donors. Titers of the 
IgG (A), IgM (B) and IgA (C) classes in both groups are shown. Cut-off values (dotted lines) 
2.8, 20 and 1.8 g mL-1, respectively, were defined as described in the Results section. HD: 
Healthy donors; noBT: RA patients under DMARD. 
Figure 2. Correlations between RA disease activity parameters and Anti-CD26 IgG 
titers in the anti-CD20 BT group. Statistically significant correlations between the IgG 
isotype with TJC (A), SJC (B), DAS28 (C) and PGA (D) were detected in the group of RA 
patients treated with anti-CD20 antibodies.
Figure 3. Anti-CD26 Abs are not ACPA. (A) Supernatants recovered from the ACPA test 
after incubation of serum from 3 different RA patients (filled columns) and 3 different healthy 
donors (clear columns) were subsequently used for the Anti-CD26 test. Similar absorbance 
values were observed when the same serum samples were used directly in the Anti-CD26 test 
(data not shown). (B) Absorbance values for the same subjects tested in (A) in the ACPA test 
(dark grey columns) and for the supernatants from the serum samples tested previously in the 
Anti-CD26 test (clear gray columns). In two cases, one RA patient (rightmost) and one 
healthy donor (leftmost), there were differences between both absorbance values pointing to 
the possibility that some of the ACPA autoantibodies bind to CD26. Background values were 






























































Figure 4.  Correlations of Anti-CD26, or Total Ig titres of the three isotypes (A,G or M), 
or their ratios (Anti-CD26/Total), with serum sCD26 concentration and DPP-IV 
enzymatic activities in the cohort of RA patients under different therapies.  Correlations 
found in patients under DAMARDs (noBT) (A), anti-TNF BT (B), anti-CD20 BT (C) and 
anti-IL6R/Ig-CTLA4 BT (D) therapies, for Total Ig titres (tIgG, tIgM or tIgA; black 
columns), Anti-CD26 (aIgG, aIgM or aIgA; grey columns), or their ratios (rIgG, rIgM or 
rIgA; empty columns) against both sCD26 serum levels and DPP-IV enzymatic activity, are 
shown. r: Pearson’s correlation coefficient, and * p<0.05, ** p<0.005 are indicated. Only in 































































3.2. Serum Anti-CD26 and Total Ig levels in RA patients undergoing different 
therapies 
In the anti-CD20 BT group, impaired levels of Total IgG and particularly IgM 
compared to the group without BT (noBT) were found, as expected (anti-CD20 
deletes Ab-producing cells) whereas no effect in Total IgA was seen (Table 1). Those 
drops did not reach the Ig levels of healthy donors. On the contrary, increased levels 
of both IgG and IgM were found in the other groups (Table 1). The anti-IL6R/Ig-
CTLA4 BT group was the only one showing slightly lower levels of IgA.  
The results for Anti-CD26 were different to that of Total Igs, underlying the 
specificity of the ELISA: The IgG isotype was not affected by any therapy; anti-CD20 
strongly reduced only IgM, and finally IgA was affected by both anti-TNF and anti-
IL6R/Ig-CTLA4 therapies but in contrary directions (Table 1). As consequence, ratios 
for the three isotypes are quite different compared to healthy subjects, particularly 
IgM for anti-TNF and anti-IL6R/Ig-CTLA4 BT, IgA for anti-CD20 BT and IL6R/Ig-
CTLA4 BT, and IgG for noBT and IL6R/Ig-CTLA4 BT. Most of these differences 
were statistically significant (see Table 1).  The same can be concluded when 
checking the isotype ratios (A/M, G/A, G/M) for Total or for Anti-CD26 titers: 
statistically significant differences between patients and donors in some ratios 
(Supplemental Table 1) and important differences among the therapies (Supplemental 
Figure 1, check the different behaviour of the G/A ratio in Total and Anti-CD26 titers 
in the anti-CD20 BT group). 
	
 
3.4. Correlations of serum Anti-CD26 levels with disease activity parameters in RA 
patients 
Total Ig (which include RF and ACPA) titers of the three isotypes did not 
correlate with the DAS28 score in the whole cohort, however some statistically 
significant correlations were found with ESR (r= 0.272, p=0.005 for IgM; r= 0.213, 
p=0.028 for IgG; r= 0.280, p=0.004 for IgA). Moreover, IgG negatively correlated 
with TJC and IgM with HAQ (data not shown).  
Correlations between the Abs in each group of patients undergoing different 
therapies (which serve as internal controls of the results shown) were (data not 
shown): In the noBT group, strong correlations between all Total Ig titers are 
observed (and show correlations with the platelet count) but in Anti-CD26, only IgA 
and IgM showed a correlation between them. In the anti-TNF BT group, Total IgA 
did not correlate with the other two isotypes and showed only a positive correlation 
with the ESR. Total IgM also correlated positively with Hb and haematocrit and 
negatively with the CRP whereas IgG correlated negatively with the ESR and the 
platelet count. In the anti-CD20 BT group, Total Igs did not correlate among them 
and the only correlations detected were IgM ratio with both HAQ and PGA, and IgG 
ratio with platelets. In the anti-IL6R/Ig-CTLA4 BT group, Total IgA did not correlate 
with the other isotype (as in the anti-TNF group) and Anti-CD26 IgA and IgM did not 
correlate between them (in contrast to the noBT group). Anti-CD26 Igs in the other 









SUPPLEMENTARY FIGURE LEGENDS 
 
Sup Figure 1. Therapy effect on Total and Anti-CD26 IgG, IgM and IgA ratios. 
Ratios for either Total (upper row) and Anti-CD26 Ig levels (lower rows) in patients 
grouped according to treatment are shown. Columns 1: NoBT (DAMARDs); columns 
2: anti-TNF-α ΒΤ; columns 3: anti-CD20 BT; columns 4: anti-IL6R/Ig-CTLA4 BTs 
(grouped together). The effects on the different ratios were usually the opposite in the 
case of Anti-CD26 to that observed for Total Ig levels (compare lower and upper 
rows). 
 
Sup Figure 2. COR curves for the Anti-CD26, Total Ig titers and their ratios in 
the whole cohort with respect to the control donors.  Anti-CD26 IgG (see text) and 
IgM show better curves (AUC: 0.897, p<0.001 and 0.756, p<0.001, respectively) than 
their Total Ig counterparts (AUC: 0.698, p=0.002 and 0.647, p=0.022, respectively). 
However, Total IgA isotype (AUC: 0.978, p<0.001) showed the best results while 
their ratio showed the worst. 
 
Sup Figure 3. Correlations between RA disease activity parameters and Anti-
CD26 IgA titers in the anti-TNF BT group. (A) Correlation between the IgA 




















		 Controls	(n=25)	 RA	patients	(n=106)	 	 	
		 Mean	±	SD	 	 Mean	±	SD	 	 	 	 	 	
Total	Ig	ratio	A/M	 1.3	±	1.0	 	 3.7	±	6.7**	 	 	 	 	 	
Total	Ig	ratio	G/A		 5.4	±	1.3	 	 4.8	±	7.3	 	 	 	 	 	
Total	Ig	ratio	G/M		 6.7	±	5.2	 	 11.3	±	18.6*	 	 	 	 	 	
Auto	Ig	ratio	A/M		 0.11	±	0.04	 	 0.13	±	0.21	 	 	 	 	 	
Auto	Ig	ratio	G/A		 1.7	±	0.6	 	 7.5	±	27.1	 	 	 	 	 	








Table 1. Levels of Total and Anti-CD26 Ig isotypes in RA patients under different therapies
 
n= number of samples; BT= biological therapy; CI= confidence interval; SD= standard deviation.
* Values significantly different among groups (not specified) at p < 0.05 with Student´s t test
+ Values significantly different to those of no biological therapy (No BT) group at p < 0.05 with Dunnett’s t test
 No BT (n=22) Anti-TNFα BT (n=58) Anti-CD20 BT (n=11) Anti-IL6R/Ig-CTLA4 BT (n=15)
 Mean ± SD CI (95%) Mean ± SD CI (95%) Mean ± SD CI (95%) Mean ± SD CI (95%)
Anti-CD26 IgM (g/mL) 30.30 ± 20.49*   21.21-39.38 27.92 ± 18.08 23.16-32.67 16.85 ± 15.15* 6.67-27.03 32.94 ± 21.82 20.85-45.02
Anti-CD26 IgA (g/mL) 1.76 ± 0.92* 1.35-2.17 2.32 ± 1.51* 1.92-2.72 1.81 ± 1.44* 0.85-2.78 1.34 ± 0.71* 0.95-1.73
Anti-CD26 IgG (g/mL) 5.60 ± 3.13 4.21-6.98 6.08 ± 3.15 5.25-6.91 5.69 ± 3.68 3.21-8.16 5.62 ± 2.83 4.05-7.19
Total IgM (mg/mL) 3.26 ± 3.28* 1.80-4.71 5.22 ± 3.95* 4.18-6.26 2.23 ± 2.26* 0.71-3.74 4.02 ± 3.92 1.85-6.19
Total IgA (mg/mL) 5.56 ± 2.04 4.65-6.46 5.86 ± 1.82* 5.38-6.34 5.46 ± 1.11 4.71-6.21 4.81 ± 1.38* 4.05-5.58
Total IgG (mg/mL) 17.73 ± 12.68 12.11-23.35 24.23 ± 17.1* 19.74-28.73 15.73 ± 11.35* 8.10-23.35 22.85 ± 12.76 15.78-29.91
Ratio IgM (g/mg) 20.75 ± 25.75 10.42 ±13.12* 26.36 ± 33.05* 30.79 ±51.75*
Ratio IgA (g/mg) 0.49 ± 0.67 0.47 ± 0.63* 0.32 ± 0.24* 0.29 ± 0.16*










































Table 2. Titers of anti-CD26 Ig isotypes in RA patients under different therapies according to their smoking status
 
n= number of samples; BT= biological therapy; SD= standard deviation; 
* Value significantly different at p < 0.05 with Student´s t test between groups classified according to their smoking status (past smokers vs 
non smokers). Groups were compared only inside each type of therapy.
 No BT (n=22) Anti-TNFα BT (n=58) Anti-CD20 BT (n=11) Anti-IL6R/Ig-CTLA4 BT (n=15)
 Mean ± SD (n) Mean ± SD (n) Mean ± SD (n) Mean ± SD (n)
Non smokers 22.4 ± 18.0  (12) 25.4 ± 19.0 (33) 13.5 ± 7.7 (3) 37.1 ± 25.5 (10)
Anti-CD26 IgM (g/mL) Smokers 28.6 ± 3.8 (2) 33.0 ± 16.5 (13) 9.7 ± 9.1 (4) - -
Past smokers 42.6 ± 21.7* (8) 29.6 ± 18.0 (11) 25.6 ± 22.0 (4) 24.6 ± 8.3 (5)
Non smokers 4.6 ± 3.2 5.9 ± 3.4 4.8 ± 4.0 5.7 ± 3.1
Anti-CD26 IgG (g/mL) Smokers 8.1 ± 1.6 6.0 ± 2.9 4.0 ± 2.0 - -
Past smokers 6.4 ± 2.9 6.9 ± 2.7 7.9 ± 4.0 5.6 ± 2.7
Non smokers 1.6 ± 0.8 2.4 ± 1.6 1.4 ± 2.1 1.3 ± 0.8 
Anti-CD26 IgA (g/mL) Smokers 1.7 ± 1.4 2.1 ± 1.3 2.1 ± 0.8 - -
Past smokers 2.0 ± 1.0 2.4 ± 1.6 2.1 ± 1.2 1.5 ± 0.7
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